Funding · last 3 months
Waiting for Compass
Live medtech trackerJump to section:
Live updates powered by Compass AI
Real-time global intelligence on private companies, funding, and more insights sourced from LSI's primary research and three global summits.
Funding · last 3 months
Waiting for Compass
Funding · last 12 months
Waiting for Compass
Deals · last 3 months
Waiting for Compass
Deals · last 12 months
Waiting for Compass
Explore the full Compass AI platform to source and close your next investment, acquisition, partner or customer.
Diagnostics · Funding · last 3 months
Waiting for Compass
Diagnostics · Funding · last 12 months
Waiting for Compass
Diagnostics · Deals · last 3 months
Waiting for Compass
Diagnostics · Deals · last 12 months
Waiting for Compass
Chart preview — not live figures yet
Live Compass data is loading
See the full platform with every company, deal, investor and signal behind this tracker and beyond.
Live Compass data is loading
Live Compass data is loading
Explore every company, deal, investor and signal behind this tracker in the full platform.
Live Compass data is loading
Live Compass data is loading
See which investors are actively writing checks in your market and stage.
Chart preview — not live figures yet
Live Compass data is loading
Live Compass data is loading
Oct 18, 2026Resonant Link Medical is expanding what's possible for implantable devicesProfile of CEO Omari Bouknight
Oct 16, 2026LSI alumni achievements driving medtech and healthtech forwardMilestones from CMR Surgical, Nami Surgical and more
Oct 11, 2026Chipiron is rebuilding MRI from first principlesProfile of co-founder and CEO Evan Kervella279 M&A30 IPOsSince Q1 2023
Integra LifeSciences reported third-quarter 2026 revenue of $411.2 million, up 2.3% year over year on a reported basis.
Abbott received CE Mark for its Cologuard Plus colorectal cancer screening test under the European Union’s IVDR.
Johnson & Johnson launched its Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S.
The FDA approved GSK and Ionis Pharmaceuticals’ bepirovirsen for adults with chronic hepatitis B virus infection who meet specified treatment and biomarker criteria.
Abbott received CE Mark approval under the EU’s IVDR for its Cologuard Plus colorectal cancer screening test.
Danaher reported third-quarter 2026 net earnings of $1.2 billion, or $1.71 per diluted common share, up 34.5% year over year.
Felix will offer GRAIL's Galleri multi-cancer early detection test to eligible patients in Ontario through its virtual care platform in the coming weeks.
Amgen and AstraZeneca reported complete Phase III CROSSING results for Tezspire in adolescent and adult patients with uncontrolled, symptomatic eosinophilic oesophagitis.
The largest listed medtech companies, with AI summaries of the news moving each stock.
The group average rose 2.83%, with most listed stocks advancing. Smith & Nephew led gains at 5.64%, while Dexcom fell 2.42% and Danaher fell 1.76%.
Johnson & Johnson rose 3.81%. Headlines report Cerenovus and Biosense Webster being incorporated into Johnson & Johnson MedTech, alongside the launch of a new coronary IVL catheter that cuts treatment times in half; the brand-incorporation headline appeared twice.
Abbott rose 1.99%. Headlines report completed enrollment in an IVL study and the start of a TriClip study amid rising heart-valve repair competition, as well as an initiated real-world study of TriClip in leaky heart valves.
Danaher fell 1.76%. Headlines report that Danaher promoted Julie Sawyer Montgomery to CEO from within. The company also reported third-quarter 2026 results.
Intuitive Surgical rose 3.67%. Headlines report a 10% stock surge tied to da Vinci 5 demand and a full rollout set for 2025. The company also received grants for haptic feedback control for hand-actuated selector click events and for a surgical instrument with an insert guide member for procedures.
Medtronic rose 3.83%. Headlines report an expanded European CE-mark indication for the Affera system to treat ventricular arrhythmias, including VT. The announcement also names the Affera Mapping and Ablation System and Sphere-9 Catheter.
Stryker rose 3.19%. Headlines say the company posted Q2 beats and narrowed guidance after progress recovering from a cyberattack, while catching up on orders and manufacturing. Stryker also fully launched its Mako robotic power system for knee surgery in the US.
Diagnostics · Funding · last 3 months
$678M
▼ 40.1% vs. prior 3 months
Diagnostics · Funding · last 12 months
$2.5B
▲ 8.4% vs. prior 12 months
Diagnostics · Deals · last 3 months
20
▲ 2 vs. prior 3 months
Diagnostics · Deals · last 12 months
70
▼ 122 vs. prior 12 months